LENZ Therapeutics (LENZ) Liabilities and Shareholders Equity (2020 - 2026)

LENZ Therapeutics (LENZ) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $272.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 35.42% year-over-year to $272.5 million; the TTM figure through Mar 2026 stood at $1.0 billion (up 19.36% YoY), while the FY2025 annual figure was $305.9 million, up 42.07% from the prior year.
• Liabilities and Shareholders Equity eased to $272.5 million in Q1 2026 per LENZ's latest filing, from $305.9 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $378.6 million in Q1 2022 and bottomed at $70.4 million in Q4 2023.
• Historically, Liabilities and Shareholders Equity has averaged $258.2 million across 5 years, with a median of $266.2 million in 2023.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity tumbled 78.14% — and 2024, when it jumped 205.93%.
• LENZ Therapeutics' Liabilities and Shareholders Equity stood at $321.9 million in 2022, then sank by 78.14% to $70.4 million in 2023, then surged by 205.93% to $215.3 million in 2024, then soared by 42.07% to $305.9 million in 2025, then retreated by 10.9% to $272.5 million in 2026.
• Business Quant data shows LENZ's Liabilities and Shareholders Equity at $272.5 million in Q1 2026, $305.9 million in Q4 2025, and $210.7 million in Q3 2025.